Investigational drug to treat Gastric or Gastroesophageal Junction Cancer
Darren Sigal, M.D.
The purpose of this study is to test the safety, tolerability, and effectiveness of an investigational drug, Relatlimab, when used in combination with another drug, Nivolumab, plus standard chemotherapy in patients with gastric or gastroesophageal junction cancer. All treatments and physician visits during this study will take place at Scripps Clinic Torrey Pines.
Be 18 years of age or older
Have unresectable, locally advanced, or metastatic gastric cancer or gastroesophageal junction adenocarcinoma
Have the following documented biomarkers: LAG-3 and PD-L1 status
Have received prior systemic treatment for this diagnosis
Be pregnant or breastfeeding
Have a history of HIV, hepatitis B or hepatitis C
Have untreated known brain or spinal cord metastases
Relatlimab and Nivolumab are human monoclonal antibodies, a type of human protein that your immune system uses to destroy foreign molecules like cancer cells, bacteria, and viruses. These drugs are being tested to see if they will allow the body’s immune system to work against tumor cells to prolong survival and delay worsening of the cancer. Nivolumab is approved by the FDA for the treatment of several cancers including head/neck, renal cell, and melanoma, but it is not approved for gastric cancer.
Patients in this study will be randomly assigned (by chance) to receive Relatlimab plus Nivolumab in combination with chemotherapy OR Nivolumab alone in combination with chemotherapy.